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SHORT COMMUNICATION
Mutation analysis of the c-mos proto-oncogene and the endothelin-B
receptor gene in medullary thyroid carcinoma and phaeochromocytoma
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Summary The characteristic tumours of MEN 2 are medullary thyroid carcinoma (MTC) and
phaeochromocytoma. Somatic RET mutations have been found in only 23-40% of sporadic MTC and
10% ofsporadic phaeochromocytomas. Thus, we sought other genes which may play a role in the pathogenesis
of these tumours. We carried out direct sequence analysis of human c-mos and human ENRB in a series of
sporadic MTC and phaeochromocytomas to determine if somatic mutations in these two genes could account
for some of the sporadic MEN 2-related tumours in which no RET mutations are detected. No somatic
mutations were found.
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Multiple endocrine neoplasia type 2 (MEN 2) is an
autosomal dominantly inherited cancer syndrome associated
with germline mutations in the RET proto-oncogene, which
codes for a receptor tyrosine kinase expressed in tissues and
tumours of neural crest origin (Bolino et al., 1995; Carlson et
al., 1994; Donis-Keller et al., 1993; Eng et al., 1994, 1995c;
Hofstra et al., 1994; Mulligan et al., 1993, 1994, 1995). MEN
2 is characterised by the presence of MTC and phaeochro-
mocytoma. Somatic RET mutations have been detected in
23-40% of sporadic MTC in series comprising ten or more
tumours (Eng et al., 1994, 1995b; Hofstra et al., 1994;
Komminoth et al., 1995; Zedenius et al., 1994) and 10-20%
of sporadic phaeochromocytomas (Beldjord et al., 1995; Eng
et al., 1994, 1995a; Lindor et al., 1995).
The human c-mos proto-oncogene encodes a serine-
threonine protein kinase expressed at high levels in germ
cells (reviewed in Yew et al., 1993). It is required for meiosis
and plays a role in the initiation of oogenesis (Colledge et al.,
1994; Sagata et al., 1988). Transgenic mice ectopically
overexpressing mos develop medullary thyroid carcinomas
(MTC) and phaeochromocytomas (Schulz et al., 1992). The
endothelin-B receptor gene (ENRB) codes for a G-protein-
coupled receptor, which is expressed in several tissues,
including the kidneys, adrenal medulla and phaeochromocy-
tomas (reviewed in Davenport, 1996; Davenport et al., 1994).
Recently, germline mutations in ENRB have been found in
patients with Hirschspung disease (HSCR) (Puffenberger et
al., 1995), a common congenital condition characterised by
the lack of enteric ganglia leading to intestinal obstruction
(Okamoto and Ueda, 1967). Up to 40% of patients with
HSCR have mutations in the RET proto-oncogene (Attie et
al., 1995).
To determine if mutations in the c-mos or ENRB genes
play a role in the pathogenesis of the sporadic tumours in
which no RET mutations have been detected, the coding
sequence of c-mos and ENRB was examined in DNA from
ten sporadic MTC and ten sporadic phaeochromocytomas
which do not have known somatic RET mutation.
Materials and methods
Tumours
The ten MTCs and nine of ten phaeochromocytomas studied
here have been described previously (Eng et al., 1994,
1995a,b). The remaining phaeochromocytoma was a uni-
lateral tumour occurring in a patient without first- or second-
degree relatives with these syndromes, known phaeochromo-
cytoma or MTC, or other stigmata of MEN 2/von Hippel-
Lindau disease. Genomic DNA was extracted as described by
Mathew et al. (1987).
Polymerase chain reaction (PCR) and DNA sequence analysis
PCR was performed, using 50-100 ng of template genomic
DNA and red hot Thermus icelandicus DNA polymerase,
according to the manufacturer's recommendations (Advanced
Biotechnologies, Surrey, UK) in the presence of 1.5 mM
magnesium chloride.
A total of 30 to 40 cycles of amplification were carried out
at 95°C for 1 min, 59°C (c-mos) or 60°C (ENRB) for 1 min
and 72°C for 1 min, followed by a final 10 min cycle at 72°C.
For c-mos, primer pairs used were Hu Mos IF (5'-TC-
TTCATTCACTCCAGCGG-3') and Hu Mos IR (5'-AAGT-
CGCCTTGTACACCGAG-3'), Hu Mos 2F (5'-GGTGTG-
CTTGCTGCAGAG-3') and Hu Mos 2R (5'-CGCCATA-
GATGACTTGGTGT-3'), Hu Mos 3F (5'-CCTAGGGAC-
CATCATCATGG-3') and Hu Mos 3R (5'-GTGTCTGG-
AAGCACAGCAGA-3') or Hu Mos 4R (5'-GGACGGGCG-
CAGGTCGTAGGCCAC-3'), and Hu Mos 4F (5'-TCAGT-
GAGCAGGATGTCTGTAA-3') and Hu Mos 5R (5'-CT-
TGACCAAGTTTTCAGTCAGC-3'). For ENRB, the primer
pairs used were ETB-OF (5'-CACACCCCTTCCAGAACG-3')
and ETB-1R (5'-CGCCCTTTACCTTGTAGACATT-3')
[exon 1], ETB-2Fa (5'-CTGCTGGCAGAGGACTGG-3')
and ETB-13R (AAGGAGTGGGGAACAGGG-3') [exons 2
and 3], ETB-44F (5'-GCTATGAGTAAAATGAGCCAT-3')
and ETB-15R (5'-CTGCCTATAAAAAAGATCGATGG-3')
[exon 5], ETB-5F (5'-CAGGATTCTGAAGCTCACTCTTT-
3') and ETB-46R (5'-TGTTTAAAAAAATCATCCATGA-3')
[exon 6], and ETB-16F (5'-ATACAAAGAAAGTCAGAA-
CCCTGG-3') and ETB-8R (5'-TTTTTGTTTTGTTTTGG-
CAAAT-3') [exon 7]. Primers for exon 4 have been previously
described (Puffenberger et al., 1995).
PCR products were gel and column purified (Eng et al.,
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1994). Twenty aliquots of 100 ng of PCR product served as
the template for cycle sequencing (Cyclist kit or the Cyclist
Exo-Pfu DNA sequence kit, Strategene). Sequence variants
were confirmed by digestion with an appropriate restriction
enzyme.
Results
No somatic mutations were detected in the coding sequence
of c-mos or the endothelin-B receptor gene among ten
sporadic MTC and ten sporadic phaeochromocytomas. In
addition, all PCR products were the expected sizes,
suggesting no deletions or splicing variants which could
have been missed by sequence analysis.
A novel sequence polymorphism was detected within the
kinase domain of c-mos: a G (A1) to T (A2) conversion,
changing an alanine to a seine at codon 105. This causes loss
of a BlpI restriction site. The Al and A2 alleles occurred at
frequencies of 0.85 and 0.15, respectively, among 122
Caucasian chromosomes.
Discussion
Although the tumours that developed in transgenic c-mos
mice resembled those of MEN 2, suggesting that the human
homologue may be involved in MEN 2-related tumours, no
somatic c-mos mutations or rearrangements could be found
in human MTC or phaeochromocytomas. However, gene
amplification in the tumours could not be excluded with our
analyses, and sufficient DNA was not available for gene
dosage studies. The lack of c-mos mutations in human
tumours might be because in transgenic mice, the mos
constructs were transcribed from the Moloney murine
sarcoma virus LTR, a relatively strong promoter which
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may also cause ectopic patterns of expression; or because of
species-specific differences. Finally, it is possible that c-mos
may play a role in rare MTC and phaeochromocytomas but
the numbers examined precluded detection. In light of our
data, it is interesting to note that in vitro, many deletion or
missense mutations of conserved residues, except for one 10-
residue deletion, in Xenopus mos result in the elimination of
biological and kinase activity (Fukasawa et al., 1995).
The finding of germline mutations of ENRB in HSCR and
its expression pattern suggested that this gene would be a
good candidate for involvement in the pathogenesis of MTC
and phaeochromocytoma. However, no mutations were
detected. Thus, mutation of neither human c-mos nor ENRB
appears to play a major role in the tumorigenesis of MTC
and phaeochromocytomas.
A novel sequence polymorphism in the kinase domain of
c-mos was detected. The polymorphisms could serve as a
useful marker in the region of human c-mos on chromosome
subband 8ql2, and may in addition help in the understanding
of computer-modelled structure-function relationships of
kinase domains.
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